A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
5148
NCT00035035
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
New Britain, Connecticut 06052 | |
Birmingham, Alabama 35294 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Albany, New York 12208 | |
Cleveland, Ohio 44195 | |
Philadelphia, Pennsylvania 19104 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Seattle, Washington 98195 | |
Louisville, Kentucky 40207 | |
Kansas City, Kansas 66160 | |
Scarborough, Maine 04074 | |
Omaha, Nebraska 68114 | |
Albuquerque, New Mexico 87131-5636 | |
Metairie, Louisiana 70006 | |
Denver, Colorado | |
Boston, Massachusetts | |
Milwaukee, Wisconsin | |
Indianapolis, Indiana | |
Charleston, South Carolina |